^[1] Johannes Duell, M.D., et al. Long-term analyses from L-MIND, a Phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract #7513. ^[2] Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014. ^[3] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421. ^[4] Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421. -----------------------------------------------------------------------------------------------------------------------

2021-06-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        +49 (0)89 899 27-0 
Fax:          +49 (0)89 899 27-222 
E-mail:       investors@morphosys.com 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1204635 
 
End of News   DGAP News Service 
=------------

1204635 2021-06-04


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1204635&application_name=news

(END) Dow Jones Newswires

June 04, 2021 13:33 ET (17:33 GMT)